Interpol teams up with pharma


International police service Interpol is teaming up with 29 drug companies to combat the trade in fake medicines.

The group will spend €4.5 million (£3.9 million) to create a pharmaceutical crime programme, which will build on the work of Interpol's Medical Product Counterfeiting and Pharmaceutical Crime (MPCPC) unit.

The programme will seek to raise awareness of the dangers of fake drugs, particularly those bought online. According to the World Health Organization, in more than 50% of cases, medicines purchased over the internet from illegal sites that conceal their physical addresses are counterfeit.

Counterfeit cough syrup and other medicines laced with diethylene glycol have caused eight mass poisonings around the world. In 2006, more than 100 people in Panama, many of them children, died after taking contaminated cough syrup. In 2012, over 100 heart patients in Pakistan died after taking fake medicine.

Pharmaceutical crime includes manufacture, trade and distribution of fake, stolen or illicit medicines or medical devices.


Related Content

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

Chinese police seize £222m of fake drugs

20 December 2013 Business

news image

1300 people are arrested in a nationwide crackdown on counterfeit medicines

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent